Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.
Sebastian Håkansson(Lund University), Åke Borg(Lund University), Unn‐Britt Johansson(Sophiahemmet University College), Charlott Sellberg, Nikos Pandis, Anne‐Marie Gerdes(Copenhagen University Hospital), Niklas Dahl(Uppsala University), Ulf Kristoffersson, Niklas Loman(Lund University), Eva Holmberg(University of Gothenburg), Óskar Þór Jóhannsson(National University Hospital of Iceland), Håkan Olsson(Nokia (Finland))
PubMed
May 1, 1997
Cited by 178
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
The Life History of 21 Breast Cancers
|Cell|2012|1.5k